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prospectively collected data on 1958 consecutive HSCTs per-
formed between 1995 and 2004 and compared patients with
DAH and infection associated alveolar hemorrhage (IAH) who
presented with similar hypoxemia, pulmonary inﬁltrates, and
progressively bloody alveolar lavage but also had microorgan-
isms (excluding Aspergillus spp) isolated from blood, bronchoal-
veolar lavage (BAL), or tracheal aspirate within 1 week of
alveolar hemorrhage. Overall, 116 (5.9%) patients had alveolar
hemorrhage diagnosed by BAL (DAH  45, IAH  71). Sixty-
day mortality from the onset of alveolar hemorrhage was 74%
(95% conﬁdence-interval (CI), 66–82%). For the whole cohort,
presence of infection (P  .04) and hemorrhage within 5 days of
engraftment (P  .01) were predictive of survival beyond 60
days from onset of alveolar hemorrhage. The DAH and IAH
groups were comparable except for greater use of total body
irradiation containing conditioning regimen in the DAH group
(P  .04) and umbilical cord blood donor source in the IAH
group (P  .04). Survival at 60 days from the onset of alveolar
hemorrhage was 16% (95% CI, 5–27%) for the DAH group and
32% (95% CI, 21%–43%) for the IAH group (P  .18). All
except 20 patients (DAH  4, IAH  16) were treated with a
standard regimen of high-dose corticosteroids. The steroid and
no-steroid groups were comparable except for a trend towards
greater use of corticosteroids in the DAH group (P  .06). Sixty
day survival from the onset of alveolar hemorrhage was 26%
(95% CI, 17–35%) in patients receiving corticosteroids com-
pared to 25% (95% CI, 6–44%) in those not receiving corti-
costeroids (P  .17). The pathogenesis of alveolar hemorrhage
following HSCT is multifactorial and we propose that IAH and
DAH are related clinical syndromes with similar clinical pre-
sentation, risks, and associated high mortality. Furthermore, our
results show no beneﬁt of high-dose corticosteroids in the
management of this disorder. Ongoing study to identify the
pathophysiologic mechanisms of alveolar injury and to deﬁne
new therapy is still needed.
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POSACONAZOLE (POS) VS FLUCONAZOLE (FLU) FOR PROPHYLAXIS OF
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ETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS WITH GRAFT-VER-
SUS-HOST DISEASE (GVHD): A MULTICENTER TRIAL
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Introduction: Allogeneic HSCT recipients are at risk for life-
threatening IFI. In patients with GVHD, IFIs are mainly due to
moulds, limiting the utility of prophylactic FLU. We compared
POS with FLU in preventing IFI in HSCT recipients with GVHD
on intensive immunosuppressives. Methods: Patients in this dou-
ble-blind, double-dummy study received oral POS (200 mg tid) or
FLU (400 mg qd) for up to 16 weeks (112 days). Incidence of IFI
was determined at 16 weeks and up to 7 days after last dose by
EORTC/MSG criteria adjudicated by a blinded expert panel. Re-
sults: 600 patients were enrolled (301 POS; 299 FLU). Mean
duration of therapy was 80 days in the POS arm and 77 days in the
FLU arm. Incidence of proven/probable IFIs is shown below.
Mortality rate due to IFI was POS (1%) versus FLU (4%); overall
rate was 25% versus 28%. Safety and tolerability were comparable.
Discontinuations due to treatment failure were lower for POS
versus FLU (3% vs 8%); those due to adverse events were similar
(33% each).Conclusions: POS was superior to FLU in preventing
aspergillosis and other breakthrough IFIs in HSCT recipients with
GVHD. Although POS was noninferior to FLU in preventing
total IFIs during the study period, the criteria for superiority were
not met. This may be because of the high rate of discontinuation
before day 112 (45% of POS patients and 52% of FLU patients),
contributing to the small number of IFI events. Both agents were
well tolerated (Table1).
Table 1.
Proven/Probable IFIs
POS,
n (%)
FLU,
n (%)
Odds Ratio
(95% CI)
P
Value
IFIs during study period (day 112)
Total 16 (5) 27 (9) 0.56 (0.30–1.1) .07
Aspergillus 7 (2) 21 (7) 0.31 (0.13–0.75) .006
Breakthrough infections (while on treatment)
Total 7 (2) 22 (8) 0.30 (0.12–0.71) .004
Aspergillus 3 (1) 17 (6) 0.17 (0.05–0.57) .001
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ACTIVE TREATMENT OF ASYMPTOMATIC RADIOLOGICALLY DOCU-
MENTED SINUSITIS MAY BE NECESSARY FOR PATIENTS RECEIVING
TOTAL BODY IRRADIATION CONDITIONING
Kwon, J.M.1, Jung, C.W.1, Kim, W.S.1, Kim, K.M.1, Chung, S.K.1,
Kang, W.K.1, Park, K.1 Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, Korea.
Background: In hematopoietic stem cell transplantation
(HSCT), careful evaluation of paranasal sinus is necessary be-
cause increased risk of sinusitis may be problematic during
post-transplant neutropenic period. However, there are no cri-
teria for diagnosis and optimal treatment of asymptomatic ra-
diologically documented or symptomatic sinusitis. Methods: A
retrospective review of the medical records of 256 patients who
received autologous (n  124) or allogeneic (n  128) HSCT
for hematologic malignancies at Samsung Medical Center from
April 1996 to December 2003 was performed. Four patients
were excluded because of tumor originated in nasal cavity.
Radiologically documented sinusitis was deﬁned as mucosal
thickening, opaciﬁcation and air-ﬂuid level of sinus without
symptom. Symptomatic sinusitis was deﬁned as symptoms such
as postnasal drip, rhinorrhea, nasal obstruction, cough, fever,
headache with radiologic abnormalities.
Results: The median age was 38 years (range 15–68 years). One
hundred thirty-three (52.8%) of 252 patients had no evidence of
sinusitis and 23 (9.1%) patients had symptomatic sinusitis before
transplantation. The remaining 96 patients (38.1%) had asymp-
tomatic radiologically documented sinusitis. All symptomatic si-
nusitis were treated sufﬁciently before proceeding to HSCT. Of 96
patients with radiologically documented sinusitis, but without
symptom, 54 were treated with antibiotics, 6 were operated endo-
scopically, and 36 were not treated.
After transplantation, sinusitis developed in 76 patients (30.2%), 40
(15.9%) were documented clinically and 36 (14.3%) were radiologi-
cally. Median day of onset of sinusitis was 52.5 days (range 1–420
days) after transplantation. There were no deaths or graft failure
related to sinus complications. In patients with asymptomatic radio-
logically documented sinusitis, there was no difference in the inci-
dence of post-transplant sinusitis among surgery and medical therapy
and observation (P  .479). In patients who received total body
irradiation (TBI) as conditioning regimen, radiologically documented
sinusitis was related to higher risk of developing post-transplantation
sinusitis (P  .033). Conclusions: Our data suggest that aggressive
treatment of asymptomatic radiologically documented sinusitis at pre-
transplantation may not be necessary. However, if recipient is sched-
uled to receive of TBI as conditioning regimen, active treatment of
asymptomatic radiologically documented sinusitis is to be considered.
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